IOB - Delayed Quote USD

0LKB.IL,0P0001HC7I,0 (0LKB.IL)

6.30

0.00

(0.00%)

At close: July 23 at 9:00:00 PM GMT+1

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Academy of Neurology (AAN) Annual Meeting, to be held in San Diego, California from April 5 through April 9, 2025.

PR Newswire 9 days ago

VNDA
High Growth Tech Stocks In US With Promising Potential

Over the last 7 days, the United States market has experienced a 3.0% drop, yet it remains up by 7.5% over the past year with earnings anticipated to grow by 14% annually in the coming years. In this dynamic environment, identifying high growth tech stocks involves focusing on companies that exhibit strong innovation and adaptability to capitalize on these projected earnings growth trends.

Simply Wall St. 14 days ago

BIGC

VNDA

GCI
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) requesting marketing approval of Bysanti™ (milsaperidone) for the treatments of acute bipolar I disorder and schizophrenia. The NDA is supported by several clinical studies assessing the efficacy and safety of Bysanti™.

PR Newswire 16 days ago

VNDA
US High Growth Tech Stocks With Strong Potential

Over the last 7 days, the United States market has dropped 4.8%, yet it has risen by 15% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential through innovation and adaptability to leverage these market dynamics effectively.

Simply Wall St. last month

KNSA

FOLD

VNDA
February 2025 Penny Stocks To Keep An Eye On

As February 2025 unfolds, the U.S. stock market has shown signs of resilience with the S&P 500 and Nasdaq Composite inching higher after a four-day losing streak, despite ongoing concerns about the economic outlook. In this context, penny stocks—often representing smaller or newer companies—continue to capture investor interest due to their affordability and potential for growth. While traditionally viewed with caution, these stocks can offer unique opportunities when backed by strong...

Simply Wall St. last month

VNDA

RERE
Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article entitled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" in Molecular Therapy Nucleic Acids1, a Cell Press partner journal, that describes the development of a novel antisense oligonucleotide (ASO) therapeutic, VCA-894A, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S).

PR Newswire last month

VNDA
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2024.

PR Newswire 2 months ago

VNDA
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2024 on Thursday, February 13, 2025, after the market closes.

PR Newswire 2 months ago

VNDA
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing BLA and MAA applications for the US and EUAnaptys to receive $15 million from Vanda, comprised of a $10 million upfront payment and $5 million for existing drug supplyAnaptys to receive a 10% royalty on global net sales of imsidolimab WASHINGTON and SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and Anaptys

GlobeNewswire 2 months ago

VNDA

ANAB
US Exchange Penny Stocks To Watch In January 2025

The U.S. stock market has recently experienced volatility, with the Nasdaq Composite and S&P 500 indices declining sharply due to concerns over China's advancements in artificial intelligence. Amidst these fluctuations, investors are increasingly exploring diverse opportunities, including penny stocks—an investment area that continues to intrigue despite its somewhat outdated terminology. These stocks often represent smaller or newer companies and can offer a blend of affordability and growth...

Simply Wall St. 2 months ago

VNDA

MNOV

ZNTL
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program.

PR Newswire 2 months ago

VNDA
Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review.

PR Newswire 3 months ago

VNDA
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide (ASO)-based JAK2 inhibitor for the treatment of polycythemia vera (PV), a form of a rare hematologic malignancy that is estimated to affect 1 in 2000 Americans.1

PR Newswire 3 months ago

VNDA
Exploring Three High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has experienced a 3.5% drop, yet it has shown resilience with a 22% rise over the past year and an anticipated annual earnings growth of 15%. In this dynamic environment, identifying high-growth tech stocks involves assessing their potential to capitalize on technological advancements and market trends while aligning with robust growth forecasts.

Simply Wall St. 3 months ago

VNDA

ATYR

KNSA
US Penny Stocks To Watch In December 2024

As the U.S. markets navigate a period of uncertainty with the Dow Jones Industrial Average experiencing its longest slump since 1978, investors are keenly watching for the Federal Reserve's upcoming interest rate decision. Amidst this backdrop, penny stocks—often representing smaller or newer companies—continue to capture attention due to their potential for growth at lower price points. While the term "penny stocks" may seem outdated, these investments can still offer unique opportunities...

Simply Wall St. 3 months ago

VNDA

LTRX
Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November 2024:

PR Newswire 5 months ago

VNDA
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2024.

PR Newswire 5 months ago

VNDA
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks

As the U.S. stock market navigates the complexities of a presidential election and anticipated Federal Reserve rate decisions, investors are closely watching the movements of major indices like the Dow Jones and Nasdaq. In such a climate, penny stocks—though an older term—remain relevant for those seeking investment opportunities in smaller or newer companies. These stocks often offer potential value when supported by strong financials, presenting a unique opportunity for growth at lower...

Simply Wall St. 5 months ago

KLTR

VNDA

BDTX
Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2024 on Wednesday, November 6, 2024, after the market closes.

PR Newswire 5 months ago

VNDA
Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals

Cycle Pharmaceuticals reaffirmed its proposal to acquire all of the issued and outstanding shares of Vanda Pharmaceuticals for an all-cash consideration of $8.00 per Vanda share. Cycle said it is making its renewed proposal public for the benefit of Vanda shareholders in light of the Vanda board’s continued refusal to engage following the receipt of multiple premium proposals, Vanda’s recent failure to receive FDA approval for tradipitant, following a failed Phase 3 trial that missed its primary

TipRanks 5 months ago

VNDA

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

0LKB.IL,0P0001HC7I,0 (0LKB.IL)

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

High Growth Tech Stocks In US With Promising Potential

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

US High Growth Tech Stocks With Strong Potential

February 2025 Penny Stocks To Keep An Eye On

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

US Exchange Penny Stocks To Watch In January 2025

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

Exploring Three High Growth Tech Stocks In The United States

US Penny Stocks To Watch In December 2024

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals